Prosecution Insights
Prosecution Insights
27 pending office actions • 15 art units • 25 examiners • 0 of 27 (0%) have an AI response strategy ready • 46 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (15%) |
| §102 only | 1 (4%) |
| §112 only | 5 (19%) |
| Double-patenting + other | 6 (22%) |
| Multi-statute (no §101) | 11 (41%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 2 | 51.4% | +17.1% |
| SEITZ, ANTHONY JOSEPH | 2 | 68.1% | +27.6% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.5% |
| TAO, BIN | 1 | 100.0% | +0.0% |
| SOROUSH, LAYLA | 1 | 40.4% | +43.5% |
| FADHEL, ALI Z | 1 | 76.4% | +8.8% |
| BERRY, LAYLA D | 1 | 65.9% | +8.9% |
| HOWELL, THEODORE R | 1 | 66.7% | +25.5% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.5% |
| CHAO, ALLEN | 1 | 66.7% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18759283 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | TAO, BIN | — |
| 18696850 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18479576 | 4'-THIONUCLEOSIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | OLSON, ANDREA STEFFEL | 9d overdue |
| 18345547 | THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF AN HIV VIRUS INFECTION | DEKARSKE, MADELINE MCGUIRE | 8d overdue |
| 18295163 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | HAMA, JOANNE | 2d overdue |
| 18365919 | SARS-COV2 MAIN PROTEASE INHIBITORS | BORALSKY, LUKE ALAN | 6d |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | GRIZER, CASSANDRA SENN | 8d |
| 18469844 | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY | DENT, ALANA HARRIS | 12d |
| 18754347 | METHODS AND INTERMEDIATES FOR PREPARING ANTIVIRAL PRODRUGS | FADHEL, ALI Z | — |
| 18286971 | METHODS OF PREPARING CARBANUCLEOSIDES USING AMIDES | BRANDSEN, BENJAMIN MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18344560 | CD73 COMPOUNDS | SEITZ, ANTHONY JOSEPH | 69d |
| 19255499 | TREATMENT OF HR+/HER2- BREAST CANCER USING SACITUZUMAB GOVITECAN | PUTTLITZ, KARL J | — |
| 18758879 | PROCESSES FOR MAKING IRAK4 INHIBITORS | FETTEROLF, BRANDON J | — |
| 18755378 | ANTIVIRAL COMPOUNDS | SOROUSH, LAYLA | — |
| 18639097 | DOSING REGIMEN OF CAPSID INHIBITOR | HOWELL, THEODORE R | — |
| 18696850 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA | WILLIS, DOUGLAS M | — |
| 18346745 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | FETTEROLF, BRANDON J | — |
| 18215217 | SOLID FORMS OF A NUCLEOSIDE ANALOGUE AND USES THEREOF | SEITZ, ANTHONY JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1693 | 3 |
| 1626 | 3 |
| 1646 | 2 |
| 1624 | 2 |
| 1622 | 2 |
| 1629 | 2 |
| 1628 | 1 |
| 1643 | 1 |
| 1691 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19255499 | TREATMENT OF HR+/HER2- BREAST CANCER USING SACITUZUMAB GOVITECAN | PUTTLITZ, KARL J | 1646 | §103§112DP | Final Rejection | — | Pending | Jun 30, 2025 |
| 18759283 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | TAO, BIN | — | §112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18758879 | PROCESSES FOR MAKING IRAK4 INHIBITORS | FETTEROLF, BRANDON J | — | §102§103§112DP | Final Rejection | — | Pending | Jun 28, 2024 |
| 18755378 | ANTIVIRAL COMPOUNDS | SOROUSH, LAYLA | — | §103 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18754347 | METHODS AND INTERMEDIATES FOR PREPARING ANTIVIRAL PRODRUGS | FADHEL, ALI Z | — | §102§103 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18655876 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | BERRY, LAYLA D | 1693 | §103 | Final Rejection | 5d overdue | Pending | May 06, 2024 |
| 18639097 | DOSING REGIMEN OF CAPSID INHIBITOR | HOWELL, THEODORE R | 1628 | §103§112DP | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18696850 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA | WILLIS, DOUGLAS M | 1624 | §112Other | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18512088 | METHODS FOR TREATING POXVIRUS INFECTIONS | CHAO, ALLEN | 1622 | §102 | Final Rejection | 3d overdue | Pending | Nov 17, 2023 |
| 18286971 | METHODS OF PREPARING CARBANUCLEOSIDES USING AMIDES | BRANDSEN, BENJAMIN MICHAEL | 1693 | §103§112Other | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18479576 | 4'-THIONUCLEOSIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | OLSON, ANDREA STEFFEL | 1693 | §103§112 | Non-Final OA | 9d overdue | Pending | Oct 02, 2023 |
| 18469844 | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY | DENT, ALANA HARRIS | 1643 | §102§103§112 | Non-Final OA | 12d | Pending | Sep 19, 2023 |
| 18468515 | HIV VACCINES AND METHODS OF MAKING AND USING | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §102§103 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18243812 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | LEWIS, PATRICK T | 1691 | §103Other | Non-Final OA | 25d overdue | Pending | Sep 08, 2023 |
| 18448721 | DOSING AND SCHEDULING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Final Rejection | 8d | Pending | Aug 11, 2023 |
| 18365919 | SARS-COV2 MAIN PROTEASE INHIBITORS | BORALSKY, LUKE ALAN | 1624 | §102§112Other | Non-Final OA | 6d | Pending | Aug 04, 2023 |
| 18346745 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | FETTEROLF, BRANDON J | 1626 | §112DPOther | Final Rejection | — | Pending | Jul 03, 2023 |
| 18345547 | THERAPEUTIC COMPOUNDS USEFUL FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF AN HIV VIRUS INFECTION | DEKARSKE, MADELINE MCGUIRE | 1622 | §103§112Other | Non-Final OA | 8d overdue | Pending | Jun 30, 2023 |
| 18344560 | CD73 COMPOUNDS | SEITZ, ANTHONY JOSEPH | 1629 | §112 | Non-Final OA | 69d | Pending | Jun 29, 2023 |
| 18215217 | SOLID FORMS OF A NUCLEOSIDE ANALOGUE AND USES THEREOF | SEITZ, ANTHONY JOSEPH | 1629 | §112 | Final Rejection | — | Pending | Jun 28, 2023 |
| 18268469 | 6-SUBSTITUTED INDOLE COMPOUNDS | RAO, PADMAJA S | 1627 | §103DP | Final Rejection | — | Pending | Jun 20, 2023 |
| 18205745 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | MAHLUM, JONATHAN DAVIS | 1625 | §103§112DP | Non-Final OA | — | Pending | Jun 05, 2023 |
| 18296296 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | HOWARD, ZACHARY C | 1674 | §112 | Non-Final OA | 22d overdue | Pending | Apr 05, 2023 |
| 18295163 | COMBINATION THERAPY FOR TREATING COLORECTAL CANCER | HAMA, JOANNE | 1647 | §103§112Other | Non-Final OA | 2d overdue | Pending | Apr 03, 2023 |
| 18115895 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | NOTTINGHAM, KYLE GREGORY | 1621 | §102§103§112 | Non-Final OA | — | Pending | Mar 01, 2023 |
| 17636511 | PHARMACEUTICAL FORMULATIONS OF TENOFOVIR ALAFENAMIDE | JACKSON, SHAWQUIA | 1626 | §103 | Non-Final OA | 77d | Pending | Feb 18, 2022 |
| 16882804 | THERAPEUTIC COMPOUNDS | COUGHLIN, MATTHEW P | 1626 | §102§112 | Non-Final OA | — | Pending | May 26, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial